149 related articles for article (PubMed ID: 8345035)
1. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
[TBL] [Abstract][Full Text] [Related]
2. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.
Trunet PF; Mueller P; Bhatnagar AS; Dickes I; Monnet G; White G
J Clin Endocrinol Metab; 1993 Aug; 77(2):319-23. PubMed ID: 8345034
[TBL] [Abstract][Full Text] [Related]
3. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
6. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Dowsett M; Stein RC; Mehta A; Coombes RC
Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
[TBL] [Abstract][Full Text] [Related]
7. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
Usuki S; Kondoh K; Kubo T
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Demers LM; Lipton A; Harvey HA; Kambic KB; Grossberg H; Brady C; Santen RJ
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):687-91. PubMed ID: 8476785
[TBL] [Abstract][Full Text] [Related]
9. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
11. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
12. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Demers LM
Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
[TBL] [Abstract][Full Text] [Related]
13. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC
Cancer Res; 1992 Nov; 52(21):5933-9. PubMed ID: 1394219
[TBL] [Abstract][Full Text] [Related]
14. The effects of prolonged hypertestosteronemia on adrenocortical biosynthesis in oophorectomized women.
Azziz R; Gay FL; Potter SR; Bradley E; Boots LR
J Clin Endocrinol Metab; 1991 May; 72(5):1025-30. PubMed ID: 1850751
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male.
Bhatnagar AS; Müller P; Schenkel L; Trunet PF; Beh I; Schieweck K
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):437-43. PubMed ID: 1532903
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women.
Leder BZ; Leblanc KM; Longcope C; Lee H; Catlin DH; Finkelstein JS
J Clin Endocrinol Metab; 2002 Dec; 87(12):5449-54. PubMed ID: 12466335
[TBL] [Abstract][Full Text] [Related]
17. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
18. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
[TBL] [Abstract][Full Text] [Related]
20. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
Yates RA; Dowsett M; Fisher GV; Selen A; Wyld PJ
Br J Cancer; 1996 Feb; 73(4):543-8. PubMed ID: 8595172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
